Health and Science
Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet
Many seniors may be unaware of the landmark coverage shift starting on July 1, with limited advertising seen from the government or Eli Lilly and Novo.
Estrogen patches are hard to find, and it may not be resolved any time soon
Estrogen patches are in short supply as demand for menopause treatments skyrockets, and it could take at least a year for manufacturers to catch up.
UniQure to seek FDA approval for Huntington’s disease gene therapy after previous clash with agency
The announcement comes months after UniQure became embroiled in a public debate with FDA leaders over the clinical trial data supporting its application.
Centene to offer buyouts to some employees as health insurer cuts costs
The health insurer Centene did not indicate to how many employees were offered buyouts or how much it is aiming to reduce its workforce.
Drugmakers race to find a place in the next wave of obesity drugs
Drugmakers are betting they can crack into the obesity drug market that Novo Nordisk and Eli Lilly currently dominate.
Food supply ‘not at risk’ after new Texas screwworm cases, USDA secretary says
The U.S. will lean on the same playbook it did starting in the late 1950s, part of which involves releasing sterile insects to suppress the pest’s population.
Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
Novo Nordisk and Eli Lilly bring their longtime rivalry to GLP-1 pills and prepare to make their pitch to seniors with Medicare.
As the largest World Cup ever kicks off, health officials are focused on more than Ebola
Officials are more concerned about highly contagious diseases like measles and respiratory viruses, which can spread quickly through large, fast-moving crowds.
Eli Lilly’s top dealmaker says don’t be surprised to see more M&A that pushes Lilly into new areas
Eli Lilly’s new top dealmaker explains how the company changed its approach to M&A now that it’s the most valuable pharmaceutical company in the world.
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.